Assessment of the effect of cholecalciferol ointment on atopic eczema
Phase 3
Recruiting
- Conditions
- Atopic dermatitis.Atopic dermatitis, unspecified
- Registration Number
- IRCT20100119003106N36
- Lead Sponsor
- Pharmaceutical Sciences branch, Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
aged 2-18 in both genders
discontinuation of topical treatment at least 2 weeks ago and for patients who use systemic therapy, it should be stable for months (at least 2 months) and plaque lesions remain in the use of systemic therapy
mild to moderate eczema
Exclusion Criteria
History of allergy to the compounds in the formulation and vitamin D3 derivatives
aged over 18 years
Hypervitaminosis D
hypercalcemia
Patients with acute eczema attack
The presence of skin infection or malignancy at the treatment site
The presence of diseases associated with vitamin D metabolism disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of Life. Timepoint: beginning of the treatment, 4 weeks and 8 weeks after starting the treatment. Method of measurement: questionnaire.;Eczema severity. Timepoint: beginning of the treatment, 4 weeks and 8 weeks after starting treatment. Method of measurement: EASI.
- Secondary Outcome Measures
Name Time Method Adverse effect. Timepoint: beginning of the treatment, 4 weeks and 8 weeks after starting treatment. Method of measurement: physician assessment.